Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?

AIDS. 1999 Jul 9;13(10):1278-9. doi: 10.1097/00002030-199907090-00021.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Drug Resistance, Microbial / genetics
  • Drug Therapy, Combination
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV Protease / genetics*
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Humans
  • Mutation
  • RNA, Viral / blood
  • Retrospective Studies
  • Time Factors
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral
  • HIV Protease